KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wakelee, Heather A, Liberman, Moishe, Kato, Terufumi, Tsuboi, Masahiro, Lee, Se-Hoon, He, Jie, Gao, Shugeng, Chen, Ke-Neng, Dooms, Christophe Alfons, Majem, Margarita, Eigendorff, Ekkehard, Martinengo, Gaston Lucas, Bylicki, Olivier, Rodriguez-Abreu, Delvys, Chaft, Jamie E, Novello, Silvia, Yang, Jing, Keller, Steven M, Samkari, Ayman, Spicer, Jonathan
Format: Other
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page LBA100
container_issue 17_SUPPL
container_start_page LBA100
container_title
container_volume 41
creator Wakelee, Heather A
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E
Novello, Silvia
Yang, Jing
Keller, Steven M
Samkari, Ayman
Spicer, Jonathan
description
format Other
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_739936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_739936</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7399363</originalsourceid><addsrcrecordid>eNqVTU1LwzAY7kHB6fwP71mMpM22rl5LRVAmuB30FJLmrY2mTWkStftp-3VG8Cro6fng-ThKZjRnGUnX7OkkOXXuldJ0sWbLWXK4q543D7uKrPL0Gh5Fr2yn96guQdkgDRJpdB_V0AqHwMD5oCawDQzYydEavQ-dkGBHGIyoUdqIwX0Lr_vQERlrCuoWO-tbHMUwQWONsR_RlROM6LD22vYQn3_fbCJHMZop_osXhM22vC_nyXEjjMPzHzxLLm6qXXlL3oLB8I49V26IfZ5RvqSUp1mxyHjOioKt2D_DV38Oc__p2RcJoXW2</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>other</recordtype></control><display><type>other</type><title>KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC</title><source>Lirias (KU Leuven Association)</source><source>American Society of Clinical Oncology Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Wakelee, Heather A ; Liberman, Moishe ; Kato, Terufumi ; Tsuboi, Masahiro ; Lee, Se-Hoon ; He, Jie ; Gao, Shugeng ; Chen, Ke-Neng ; Dooms, Christophe Alfons ; Majem, Margarita ; Eigendorff, Ekkehard ; Martinengo, Gaston Lucas ; Bylicki, Olivier ; Rodriguez-Abreu, Delvys ; Chaft, Jamie E ; Novello, Silvia ; Yang, Jing ; Keller, Steven M ; Samkari, Ayman ; Spicer, Jonathan</creator><creatorcontrib>Wakelee, Heather A ; Liberman, Moishe ; Kato, Terufumi ; Tsuboi, Masahiro ; Lee, Se-Hoon ; He, Jie ; Gao, Shugeng ; Chen, Ke-Neng ; Dooms, Christophe Alfons ; Majem, Margarita ; Eigendorff, Ekkehard ; Martinengo, Gaston Lucas ; Bylicki, Olivier ; Rodriguez-Abreu, Delvys ; Chaft, Jamie E ; Novello, Silvia ; Yang, Jing ; Keller, Steven M ; Samkari, Ayman ; Spicer, Jonathan</creatorcontrib><identifier>ISSN: 0732-183X</identifier><language>eng</language><publisher>LIPPINCOTT WILLIAMS &amp; WILKINS</publisher><ispartof>JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (17_SUPPL), p.LBA100-LBA100</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,780,784,27860</link.rule.ids></links><search><creatorcontrib>Wakelee, Heather A</creatorcontrib><creatorcontrib>Liberman, Moishe</creatorcontrib><creatorcontrib>Kato, Terufumi</creatorcontrib><creatorcontrib>Tsuboi, Masahiro</creatorcontrib><creatorcontrib>Lee, Se-Hoon</creatorcontrib><creatorcontrib>He, Jie</creatorcontrib><creatorcontrib>Gao, Shugeng</creatorcontrib><creatorcontrib>Chen, Ke-Neng</creatorcontrib><creatorcontrib>Dooms, Christophe Alfons</creatorcontrib><creatorcontrib>Majem, Margarita</creatorcontrib><creatorcontrib>Eigendorff, Ekkehard</creatorcontrib><creatorcontrib>Martinengo, Gaston Lucas</creatorcontrib><creatorcontrib>Bylicki, Olivier</creatorcontrib><creatorcontrib>Rodriguez-Abreu, Delvys</creatorcontrib><creatorcontrib>Chaft, Jamie E</creatorcontrib><creatorcontrib>Novello, Silvia</creatorcontrib><creatorcontrib>Yang, Jing</creatorcontrib><creatorcontrib>Keller, Steven M</creatorcontrib><creatorcontrib>Samkari, Ayman</creatorcontrib><creatorcontrib>Spicer, Jonathan</creatorcontrib><title>KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC</title><title>JOURNAL OF CLINICAL ONCOLOGY</title><issn>0732-183X</issn><fulltext>true</fulltext><rsrctype>other</rsrctype><creationdate>2023</creationdate><recordtype>other</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVTU1LwzAY7kHB6fwP71mMpM22rl5LRVAmuB30FJLmrY2mTWkStftp-3VG8Cro6fng-ThKZjRnGUnX7OkkOXXuldJ0sWbLWXK4q543D7uKrPL0Gh5Fr2yn96guQdkgDRJpdB_V0AqHwMD5oCawDQzYydEavQ-dkGBHGIyoUdqIwX0Lr_vQERlrCuoWO-tbHMUwQWONsR_RlROM6LD22vYQn3_fbCJHMZop_osXhM22vC_nyXEjjMPzHzxLLm6qXXlL3oLB8I49V26IfZ5RvqSUp1mxyHjOioKt2D_DV38Oc__p2RcJoXW2</recordid><startdate>20230610</startdate><enddate>20230610</enddate><creator>Wakelee, Heather A</creator><creator>Liberman, Moishe</creator><creator>Kato, Terufumi</creator><creator>Tsuboi, Masahiro</creator><creator>Lee, Se-Hoon</creator><creator>He, Jie</creator><creator>Gao, Shugeng</creator><creator>Chen, Ke-Neng</creator><creator>Dooms, Christophe Alfons</creator><creator>Majem, Margarita</creator><creator>Eigendorff, Ekkehard</creator><creator>Martinengo, Gaston Lucas</creator><creator>Bylicki, Olivier</creator><creator>Rodriguez-Abreu, Delvys</creator><creator>Chaft, Jamie E</creator><creator>Novello, Silvia</creator><creator>Yang, Jing</creator><creator>Keller, Steven M</creator><creator>Samkari, Ayman</creator><creator>Spicer, Jonathan</creator><general>LIPPINCOTT WILLIAMS &amp; WILKINS</general><scope>FZOIL</scope></search><sort><creationdate>20230610</creationdate><title>KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC</title><author>Wakelee, Heather A ; Liberman, Moishe ; Kato, Terufumi ; Tsuboi, Masahiro ; Lee, Se-Hoon ; He, Jie ; Gao, Shugeng ; Chen, Ke-Neng ; Dooms, Christophe Alfons ; Majem, Margarita ; Eigendorff, Ekkehard ; Martinengo, Gaston Lucas ; Bylicki, Olivier ; Rodriguez-Abreu, Delvys ; Chaft, Jamie E ; Novello, Silvia ; Yang, Jing ; Keller, Steven M ; Samkari, Ayman ; Spicer, Jonathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7399363</frbrgroupid><rsrctype>other</rsrctype><prefilter>other</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Wakelee, Heather A</creatorcontrib><creatorcontrib>Liberman, Moishe</creatorcontrib><creatorcontrib>Kato, Terufumi</creatorcontrib><creatorcontrib>Tsuboi, Masahiro</creatorcontrib><creatorcontrib>Lee, Se-Hoon</creatorcontrib><creatorcontrib>He, Jie</creatorcontrib><creatorcontrib>Gao, Shugeng</creatorcontrib><creatorcontrib>Chen, Ke-Neng</creatorcontrib><creatorcontrib>Dooms, Christophe Alfons</creatorcontrib><creatorcontrib>Majem, Margarita</creatorcontrib><creatorcontrib>Eigendorff, Ekkehard</creatorcontrib><creatorcontrib>Martinengo, Gaston Lucas</creatorcontrib><creatorcontrib>Bylicki, Olivier</creatorcontrib><creatorcontrib>Rodriguez-Abreu, Delvys</creatorcontrib><creatorcontrib>Chaft, Jamie E</creatorcontrib><creatorcontrib>Novello, Silvia</creatorcontrib><creatorcontrib>Yang, Jing</creatorcontrib><creatorcontrib>Keller, Steven M</creatorcontrib><creatorcontrib>Samkari, Ayman</creatorcontrib><creatorcontrib>Spicer, Jonathan</creatorcontrib><collection>Lirias (KU Leuven Association)</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wakelee, Heather A</au><au>Liberman, Moishe</au><au>Kato, Terufumi</au><au>Tsuboi, Masahiro</au><au>Lee, Se-Hoon</au><au>He, Jie</au><au>Gao, Shugeng</au><au>Chen, Ke-Neng</au><au>Dooms, Christophe Alfons</au><au>Majem, Margarita</au><au>Eigendorff, Ekkehard</au><au>Martinengo, Gaston Lucas</au><au>Bylicki, Olivier</au><au>Rodriguez-Abreu, Delvys</au><au>Chaft, Jamie E</au><au>Novello, Silvia</au><au>Yang, Jing</au><au>Keller, Steven M</au><au>Samkari, Ayman</au><au>Spicer, Jonathan</au><format>book</format><genre>document</genre><ristype>GEN</ristype><atitle>KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC</atitle><title>JOURNAL OF CLINICAL ONCOLOGY</title><date>2023-06-10</date><risdate>2023</risdate><volume>41</volume><issue>17_SUPPL</issue><spage>LBA100</spage><epage>LBA100</epage><pages>LBA100-LBA100</pages><issn>0732-183X</issn><pub>LIPPINCOTT WILLIAMS &amp; WILKINS</pub></addata></record>
fulltext fulltext
identifier ISSN: 0732-183X
ispartof JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (17_SUPPL), p.LBA100-LBA100
issn 0732-183X
language eng
recordid cdi_kuleuven_dspace_20_500_12942_739936
source Lirias (KU Leuven Association); American Society of Clinical Oncology Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A12%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=document&rft.atitle=KEYNOTE-671:%20Randomized,%20double-blind,%20phase%203%20study%20of%20pembrolizumab%20or%20placebo%20plus%20platinum-based%20chemotherapy%20followed%20by%20resection%20and%20pembrolizumab%20or%20placebo%20for%20early%20stage%20NSCLC&rft.au=Wakelee,%20Heather%20A&rft.date=2023-06-10&rft.volume=41&rft.issue=17_SUPPL&rft.spage=LBA100&rft.epage=LBA100&rft.pages=LBA100-LBA100&rft.issn=0732-183X&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_739936%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true